Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.19 USD | +1.24% | +1.12% | +15.37% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.37% | 8.39B | B- | ||
-11.83% | 79.26B | B+ | ||
+28.00% | 3.74B | B- | ||
-1.39% | 3.27B | B- | ||
+21.28% | 1.69B | - | ||
-3.25% | 1.56B | B | ||
-18.63% | 1.29B | C- | ||
-1.17% | 1.28B | - | ||
-6.77% | 1.14B | - | ||
+2.26% | 1.06B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ELAN Stock
- Ratings Elanco Animal Health Incorporated